NLS Pharmaceutics Current Ratio Over Time
| NLSP Stock | USD 3.66 0.10 2.81% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NLS Pharmaceutics Performance and NLS Pharmaceutics Correlation. NLS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NLS Pharmaceutics. If investors know NLS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NLS Pharmaceutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.74) | Return On Assets (2.28) | Return On Equity (8.63) |
The market value of NLS Pharmaceutics is measured differently than its book value, which is the value of NLS that is recorded on the company's balance sheet. Investors also form their own opinion of NLS Pharmaceutics' value that differs from its market value or its book value, called intrinsic value, which is NLS Pharmaceutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NLS Pharmaceutics' market value can be influenced by many factors that don't directly affect NLS Pharmaceutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NLS Pharmaceutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NLS Pharmaceutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NLS Pharmaceutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Ratio Analysis
Compare NLS Pharmaceutics and related stocks such as Neurobo Pharmaceuticals, Indaptus Therapeutics, and Pasithea Therapeutics Current Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRBO | 0.3754 | 0.3754 | 0.3754 | 0.3754 | 0.3754 | 0.4081 | 6.0049 | 2.9748 | 2.0085 | 6.781 | 2.8912 | 7.6885 | 2.8456 | 3.7772 | 2.86 |
| INDP | 25.1971 | 25.1971 | 25.1971 | 25.1971 | 25.1971 | 25.1971 | 10.7677 | 9.8039 | 5.6903 | 1.6477 | 0.8593 | 8.7719 | 7.9352 | 5.0451 | 9.25 |
| KTTA | 37.5523 | 37.5523 | 37.5523 | 37.5523 | 37.5523 | 37.5523 | 37.5523 | 37.5523 | 37.5523 | 37.5523 | 37.5523 | 119 | 18.1487 | 6.3371 | 6.02 |
| QNRX | 4.2497 | 4.2497 | 4.2497 | 4.2497 | 4.2497 | 4.2497 | 9.2961 | 6.9654 | 3.8018 | 5.1114 | 0.0583 | 0.9768 | 3.7902 | 3.1512 | 4.58 |
| ANEB | 13.5282 | 13.5282 | 13.5282 | 13.5282 | 13.5282 | 13.5282 | 13.5282 | 13.5282 | 13.5282 | 13.5282 | 82.7107 | 28.3855 | 21.0411 | 13.4621 | 12.79 |
| ACRV | 2.8042 | 2.8042 | 2.8042 | 2.8042 | 2.8042 | 2.8042 | 2.8042 | 2.8042 | 2.8042 | 2.8042 | 2.8042 | 34.4571 | 19.6057 | 9.7491 | 13.32 |
| PTIX | 0.0525 | 0.0525 | 0.0525 | 1.7376 | 0.6984 | 4.6153 | 4.6153 | 3.169 | 0.767 | 0.7032 | 1.342 | 13.8329 | 7.1756 | 6.4098 | 6.73 |
| RZLT | 0.4866 | 0.4866 | 0.1549 | 6.5428 | 3.5857 | 2.5958 | 2.7824 | 0.3213 | 1.4493 | 3.2604 | 21.3379 | 61.7807 | 20.175 | 13.393 | 8.49 |
| HCWB | 7.532 | 7.532 | 7.532 | 7.532 | 7.532 | 7.532 | 7.532 | 7.532 | 7.532 | 7.532 | 12.1355 | 17.4365 | 11.5241 | 0.7321 | 0.7 |
| MOLN | 4.7401 | 4.7401 | 4.7401 | 4.7401 | 8.6851 | 8.1999 | 11.5163 | 10.0788 | 4.1589 | 3.4931 | 3.0833 | 3.5035 | 14.7674 | 13.3504 | 14.02 |
| ASMB | 0.1742 | 14.738 | 7.4847 | 10.2822 | 27.719 | 20.0912 | 7.5235 | 9.1252 | 12.0454 | 11.5704 | 9.1881 | 9.594 | 5.9504 | 3.4108 | 3.24 |
| TIL | 6.5394 | 6.5394 | 6.5394 | 6.5394 | 6.5394 | 6.5394 | 6.5394 | 6.5394 | 6.5394 | 6.5394 | 18.5331 | 11.2196 | 8.2157 | 15.2248 | 9.56 |
| CTMX | 2.221 | 2.221 | 2.221 | 2.221 | 5.9888 | 12.0563 | 5.2604 | 6.3552 | 4.5499 | 3.544 | 3.2105 | 2.9187 | 1.5537 | 1.1733 | 1.11 |
| ACHL | 10.4012 | 10.4012 | 10.4012 | 10.4012 | 10.4012 | 10.4012 | 10.4012 | 10.4012 | 10.4012 | 26.7205 | 11.2974 | 14.9005 | 10.9254 | 8.5687 | 15.18 |
NLS Pharmaceutics and related stocks such as Neurobo Pharmaceuticals, Indaptus Therapeutics, and Pasithea Therapeutics Current Ratio description
A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.My Equities
My Current Equities and Potential Positions
| NLS Pharmaceutics AG | NLSP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Switzerland |
| Exchange | NASDAQ Exchange |
USD 3.66
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.